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OBJECTIVEdLong-term dietary intervention frequently induces a rapid weight decline fol-
lowedby weightstabilization/regain.Here,we soughtto identifyadipokinebiomarkers thatmay
reﬂect continued beneﬁcial effects of dieting despite partial weight regain.
RESEARCH DESIGN AND METHODSdWe analyzed the dynamics of fasting serum
levelsof12traditionalmetabolicbiomarkersandnoveladipokinesamong322participantsinthe
2-year Dietary Intervention Randomized Controlled Trial (DIRECT) of low-fat, Mediterranean,
or low-carbohydrate diets for weight loss.
RESULTSdWe identiﬁed two distinct patterns: Pattern A includes biomarkers (insulin, tri-
glycerides,leptin,chemerin,monocytechemoattractantprotein1,andretinol-bindingprotein4)
whose dynamics tightly correspond to changes in body weight, with the trend during the weight
lossphase(months0–6)goingintheoppositedirectiontothatintheweightmaintenance/regain
phase (months 7–24) (P , 0.05 between phases, all biomarkers). Pattern B includes biomarkers
(high molecular weight adiponectin, HDL cholesterol [HDL-C], high-sensitivity C-reactive pro-
tein [hsCRP], fetuin-A, progranulin, and vaspin) that displayed a continued, cumulative im-
provement (P , 0.05 compared with baseline, all biomarkers) throughout the intervention.
These patterns were consistent across sex, diabetic groups, and diet groups, although the mag-
nitude of change varied. Hierarchical analysis suggested similar clusters, revealing that the dy-
namic of leptin (pattern A) was most closely linked to weight change and that the dynamic of
hsCRP best typiﬁed pattern B.
CONCLUSIONSdhsCRP, HDL-C, adiponectin, fetuin-A, progranulin, and vaspin levels
displayacontinuedlong-term improvement despite partial weightregain.Thismaylikely reﬂect
eitheradelayedeffectoftheinitialweightlossoracontinuousbeneﬁcialresponsetoswitchingto
healthier dietary patterns.
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L
ong-term dietary intervention typi-
cally induces a rapid weight decline
thatstabilizesby6months.Thisweight
loss phase is followed by weight stabiliza-
tionorpartialtofullweightregaindespite
continued dieting (1). Although it is clear
that weight cycling as a result of repeated
attemptstoloseweightgreatlydiminishes
the beneﬁcial effects of healthier dietary
habits (2), whether continued long-term
dieting can indeed improve cardiovascu-
lar and metabolic risk even beyond
weight loss and despite weight regain
has remained unclear. Furthermore, it is
not well established whether certain bio-
markers primarily reﬂect weight changes
or correspond to the continued dieting in
long-term dietary intervention.
Herewesoughttoidentifyadipokines
and other biomarkers that may reﬂect
continued beneﬁcial effects of dieting,
despite partial weight regain, using new
analyses from the Dietary Intervention
Randomized Controlled Trial (DIRECT)
(3). This2-year weightloss trial was char-
acterized by high retention rates (95%
after 1 year and 85% after 2 years) and a
high level of proven adherence (4) to the
three distinct dietary strategies: low-fat,
Mediterranean, and low-carbohydrate di-
ets (3). Although the three interventions
weredifferent,inallthreegroups,thepar-
ticipants similarly increased the con-
sumption of vegetables and decreased
intake of snacks, sugared beverages, and
processed foods, suggesting a common
denominator of healthful dietary patterns
across all groups compared with baseline
(5). Diet intervention in the DIRECT
study resulted in two segments: a rapid
weight loss phase during the ﬁrst 6
monthsandapartialregain/plateauphase
during the subsequent 18 months of in-
tervention (3,6).
To determine the correspondence
between weight change dynamics and
the change among biomarkers, we used
both a nonbiased mathematical modeling
approach and qualitative analysis, assess-
ing traditional biomarkers (HDL choles-
terol [HDL-C], triglycerides [TGs], insulin,
high-sensitivity C-reactive protein [hsCRP],
highmolecularweight[HMW]adiponectin,
and leptin) and more recently discovered
adipokines, including chemerin (7), mono-
cyte chemoattractant protein 1 (MCP-1)
(8), progranulin (9), fetuin-A (10), retinol-
binding protein 4 (RBP4) (11–13), and
vaspin (14).
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Pathophysiology/Complications
ORIGINAL ARTICLERESEARCH DESIGN AND
METHODS
The 2-year DIRECT
The DIRECT, previously described in
detail (3), was conducted in one phase
between July 2005 and June 2007 in a
research center workplace in Dimona,
Israel, among 322 participants. In brief,
the trial compared the effect of low-fat,
restricted-calorie diet; Mediterranean,
restricted-calorie diet; or low-carbohydrate,
non–restricted calorie diet on long-term
weight loss and various health parame-
ters. The participants were randomized
by strata of sex, age (below or above the
median), BMI (below or above the me-
dian), history of coronary heart disease
(yes/no), type 2 diabetes mellitus (yes/
no), and current use of statins (none,
,1y e a r ,o r$1 year). Eligible partici-
pants were aged 40–65 years with BMI
$27 kg/m
2. In addition, individuals
with type 2 diabetes mellitus or coronary
heart disease were eligible regardless of
age or BMI. Pregnant or lactating women
and participants with a serum creatinine
$2m g / d L( $176 mmol/L), liver dys-
function(greaterthanorequaltotwofold
higher than the upper limit of normal in
alanine aminotransferase or aspartate
aminotransferase), intestinal problems
that would prevent adherence to any of
the test diets, or active cancer were ex-
cluded.Theparticipantsreceivednoﬁnan-
cial compensation orgifts for participating.
The study was approved and monitored
by the human subjects committee of
Soroka Medical Center and Ben-Gurion
University. Each participant provided
written informed consent.
Assessment of dietary adherence
The interventions were reported in detail
previously (3). After analyzing the recipes
using the Israeli nutritional database, we
color coded the labels of all food dishes,
for each diet type, that were served daily
in the central workplace cafeteria during
the 2-year span of the trial to promote di-
etary adherence (3).
Adherence to the diets was evaluated
by a validated food-frequency question-
naire (FFQ) (15) that included 127 food
items and three portion-size pictures for
17 items (16). A subgroup of participants
completed two repeated 24-h dietary re-
calls to verify absolute intake. At baseline
and at 6,12, and 24 monthsof follow-up,
thequestionnaireswereself-administered
electronically through the workplace intra-
net. The electronic questionnaire helped
to ensure completeness of the data by
prompting the participant when a ques-
tion was not answered, and it permitted
rapid automated reporting by the group
dietitians. The 15% of participants who
requested aid in completing the ques-
tionnaires were assisted by the study
nurse.
TheFFQs(3)revealedthattheMediter-
ranean diet group consumed the highest
dietary ﬁber and monounsaturated-to-
saturated fat ratio (P , 0.05) and that the
low-carbohydrate diet group consumed
the least carbohydrates and the most fat,
protein, and cholesterol and had a higher
percentage of positive urinary ketone de-
terminations (P , 0.05). Caloric deﬁcit
was similar among groups. The food dia-
ries obtained from a subset of participants
during the weight loss phase (4) further
showed distinct differences between low-
carbohydrateandlow-fatdiet,respectively,
in fat intake (41 vs. 26%), carbohydrate
intake (28 vs. 48%), and dietary choles-
terol intake (358 vs. 174 mg/day).
Measurement of outcome parameters
Body weight was measured every month
without shoes to the nearest 0.1 kg.
Height was measured to the nearest mil-
limeter with the use of a wall-mounted
stadiometer at baseline for BMI determi-
nation. A blood sample was drawn by
venipuncture at 8 A.M., after a 12-h fast, at
baseline and at 6 and 24 months and
stored at 2808C. Blood biomarkers were
analyzed in Leipzig University Laborato-
r i e s ,L e i p z i g ,G e r m a n y .P l a s m ai n s u l i n ,
serum hsCRP, total cholesterol, HDL-C,
LDL cholesterol, TGs, leptin, and HMW
total adiponectin were measured as de-
scribed previously (3). RBP4 was mea-
sured using an ELISA (AdipoGen, Seoul,
Korea). Serum MCP-1 concentrations
were measured by immunoassay system
(QuantikineHumanMCP-1Immunoassay;
R&D Systems Inc., Minneapolis, MN).
Serum vaspin and progranulin were
measured as previously described (14).
Serum chemerin and fetuin-A were mea-
sured by ELISAs (Biovendor, Heidelberg,
Germany).
Statistical analyses
For intention-to-treat analyses, we in-
cluded all 322 participants and used the
most recent values for weight and blood
pressure. We characterized the study pop-
ulation across quartiles of BMI and strati-
ﬁed by sex for leptin and adiponectin
because their levels signiﬁcantly differed be-
tween sexes. The pattern analysis, however,
was similar in men and women. We tested
for statistically signiﬁcant differences be-
tween different time points within di-
etary intervention groups by t test and
for given time points between dietary
groups by ANOVA. We used SPSS soft-
ware, version 18 (SPSS Inc., Chicago, IL),
and Stata software, version 9 (StataCorp
LP, College Station, TX), for the statistical
analysis.
Methods of the nonbiased approaches:
trend analysis and clustering. In the
trend analysis, we deﬁne the trends
correspondence measure (TCM) to rep-
resent the correspondence between the
t r e n di nt h eﬁrst (0–6 months) and sec-
ond (7–24 months) parts of the trial for
each biomarker. This analysis represents
the fraction of the change in the second
part of the intervention that continues
the trend observed in the ﬁrst part. For-
mally,itisdeﬁnedasfollows:Letvt
i;k rep-
resent the change in variable i in
individual k from time 0 to time t,i n
percentages of its value at time 0:
xt
i;k ≡100
xt
i;k 2 x0
i;k
x0
i;k
(1)
where xt
i;krepresents the value of that
variable in that individual at time t. Let
d
!6
i;kbe the vector connecting the points
(0, 0) and (6, v6
i;k). Let d
!24
i;k be the vector
connecting the points (6, v6
i;k) and (6,
v24
i;k 2 v24
i;k). TCM is deﬁned as the cosine
of the angle between d
!24
i;k and the line
containing d
!6
i;k (Supplementary Fig. 1).
Hierarchical clustering variables were
used. The h-clust function in R was used
with default parameters. A distance ma-
trix was derived from the TCM values of
every two variables using the following:
dA;B ¼12
 rA;B
  (2)
RESULTSdT h em e a na g eo ft h es t u d y
population was 52 6 7 years with mean
BMI of 30.9 6 3.6 kg/m
2.M o s to ft h e
participants (86%) were men. Higher
baseline BMI was signiﬁcantly associated
with increased proportion of women and
higher baseline fasting insulin, hsCRP,
leptin, and chemerin serum concentra-
tions and lower levels of HDL-C (Table 1).
A signiﬁcant sex difference was found for
leptinandadiponectin.Thethreedietinter-
ventions resulted in two segments: a rapid
weight loss phase during the ﬁrst 6 months
followed by partial or complete reversal at
the 7–24 months interval (weight mainte-
nance/regain phase) (Fig. 1A).
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Blüher and AssociatesTable 1dBaseline characteristics of the fasting blood biomarkers across quartiles of BMI stratiﬁed for sex in the DIRECT population
Baseline BMI
Entire group (N =3 2 2 ) Q1 Q2 Q3 Q4 P value*
BMI (kg/m
2)
Mean 27.1 29.2 31.4 35.8 ,0.001 30.9 6 3.6
Range 21.5–28.3 28.3–30.1 30.1–32.8 32.8–44.3
Age (years) 50.5 52 51.9 50.2 0.151 51.2 6 6.4
Men (%) 88 85 94 76 0.015 86
Fasting biomarkers
HDL-C (mg/dL)
Entire 39.9 38.4 37.8 37.8 0.035 38.5 6 9.2
Women 52.6 45.6 44.8 45.6
Men 38.4 37.1 37.3 35.4
TG (mg/dL)
Entire 165.0 171.8 169.6 177.7 0.204 171 6 87
Women 145.5 138.0 159.4 145.2
Men 166.4 178.0 170.0 188.2
Fasting insulin (mg/dL)
Entire 10.4 12.4 16.0 17.1 ,0.001 14.0 6 8.5
Women 12.2 12.7 10.6 15.8
Men 10.3 12.3 16.5 17.5
hsCRP (mg/dL)
Entire 3.1 3.9 4.4 5.5 ,0.001 4.2 6 3.2
Women 3.2 5.9 4.9 6.3
Men 3.0 3.6 4.4 5.4
Leptin (mg/dL)
Entire 6.9 10.8 12.7 20.0 ,0.001 12.5 6 10.5
Women 17.1 27.0 35.7 38.8
Men 5.6 7.9 11.1 14.3
Adiponectin (mg/dL)
Entire 7.7 7.3 6.9 7.4 0.216 7.3 6 2.8
Women 9.6 9.6 7.7 9.3
Men 7.4 6.8 6.9 6.8
Chemerin (ng/mL)
Entire 191.3 212.6 199.5 215.0 0.047 204 6 46
Women 210.4 232.8 208.6 237.4
Men 189.0 207.9 199.5 207.8
RBP4 (mg/mL)
Entire 77.2 78.2 77.4 80.1 0.473 78.2 6 32.2
Women 74.8 54.8 64.0 77.5
Men 77.7 81.9 78.0 81.3
Vaspin (ng/mL)
Entire 2.8 2.1 2.1 2.7 0.991 2.4 6 3.1
Women 4.3 2.3 2.1 1.9
Men 2.7 2.2 2.2 3.1
MCP-1 (pg/mL)
Entire 464.1 467.3 455.6 423.8 0.104 453 6 140
Women 487.8 458.0 595.9 371.4
Men 459.6 466.0 448.8 436.8
Progranulin (ng/mL)
Entire 255.1 257.1 259.1 267.5 0.567 260 6 76
Women 247.4 299.5 333.9 251.7
Men 257.2 249.9 253.8 273.0
Fetuin-A (mg/mL)
Entire 366.7 360.8 376.6 383.4 0.248 373 6 110
Women 419.8 398.0 326.7 367.8
Men 360.1 360.4 378.5 389.5
Q, quartile. *P value is age and sex adjusted.
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Adipokine dynamics and weight lossWe identiﬁed two distinct major pat-
ternsinthedynamicsofbiomarkerserum
concentrations measured at baseline and
at 6 and 24 months of intervention (Fig.
1B). The ﬁrst, pattern A, included bio-
markers whose dynamics closely corre-
sponded to changes in body weight,
exhibiting a rapid change between 0 to 6
months,duringtheweightlossphase,fol-
lowed by partial or complete reversal at
the 7–24 months interval, during the
weight maintenance/regain phase. The
following biomarkers exhibited this pat-
tern: fasting plasma insulin, TGs, leptin,
chemerin, MCP-1, and RBP4 serum con-
centrations (Fig. 1B). All biomarkers
showed a signiﬁcant difference (P , 0.05
for all) between baseline and 6 months
and between 6 and 24 months, with
chemerin and MCP-1 exhibiting a full
return at 24 months to the baseline levels
Figure 1dTwo major patterns of biomarkers during the course of 2 yearsofdietaryweight lossintervention. A:Weight loss percentages acrossthe
diet groups in the entire DIRECT population. B: Patterns of biomarkers in the entire DIRECT population. The y-axes represent the 6- and 24-month
change (D) of the biomarkers, as compared with baseline by the speciﬁc biomarker units, as indicated in Table 1. Pattern A included biomarkers
whose dynamics closely reﬂect changes in body weight, which exhibited a rapid decline (0–6 months, weight loss phase) followed by weight sta-
bilization or regain (7–24 months, weight maintenance/regain phase). All the biomarkers showed a signiﬁcant difference (P , 0.05 for all)
between baseline and 6 months and between 6 and 24 months (in the opposite direction), with chemerin and MCP-1 exhibiting a full return to
baselinelevelsat24monthsandleptin,RBP4,vaspin,progranulin,andfetuin-Aremainingsigniﬁcantlydifferentbetweenbaselineand24months
(P , 0.05).PatternBconsistedofbiomarkersthatdisplayedacontinuing,cumulativeincreaseordecreasethroughoutthe24monthsofdietary
intervention, despite the partial regain in mean body weight. All biomarkers were signiﬁcantly (P , 0.05 for all) improved after 24 months as
compared with baseline, and except for HMW adiponectin, all exhibited a signiﬁcant change between time 6 and 24 months (in the same di-
rection, P , 0.05), reﬂecting additional improvement during the weight stabilization/regain phase. Patterns A and B were similar among patients
with type 2 diabetes and nondiabetics.
care.diabetesjournals.org DIABETES CARE, VOLUME 35, FEBRUARY 2012 345
Blüher and Associatesand leptin, RBP4, vaspin, progranulin,
and fetuin-A remaining signiﬁcantly dif-
ferent between baseline and 24 months
(P , 0.05).
In sharp contrast, a second pattern of
dynamics, pattern B, could be observed
for HDL-C, hsCRP, HMW adiponectin,
fetuin-A, progranulin, and vaspin during
the 24 months of dietary intervention
(Fig. 1B). Each of these parameters dis-
played a continuing, cumulative change
in the same direction throughout the
24 months of dietary intervention, irre-
spective of weight stabilization or partial
weight regain. Consistently, all of these
biomarkers were signiﬁcantly (P , 0.05
for all) improved after 24 months as com-
pared with baseline, and except for HMW
adiponectin, all exhibited a signiﬁcant
change between 6 and 24 months (P ,
0.05), reﬂecting additional improvement
during the weight stabilization/regain
phase. It is interesting that we found sig-
niﬁcant intercorrelations at baseline be-
tween several parameters of pattern A,
whereas for parameters of pattern B, the
onlysigniﬁcantcorrelationswerefoundbe-
tween adiponectin and CRP, adiponectin
andHDL-C,andCRPandHDL-C(Supple-
mentary Table 1).
We next used a nonbiased hierar-
chical clustering approach to analyze the
dynamicsofthevariousparameterstested
at baseline and at 6 and 24 months and to
furtherunderstandtheextentofsimilarity
of trends within the clusters (i.e., to quan-
tify the distance from the weight change
pattern).Ahierarchicalclusteringdendro-
gram depicts the results of this analysis
(SupplementaryFig.2),revealingthatlep-
tin is the parameter whose dynamic most
closelycorrespondedduringthe24-month
period of dietary intervention to that of
body weight, followed by insulin, chem-
erin, and MCP-1 (Supplementary Fig. 2).
Of interest, several parameters showed a
distinct pattern that differed from the pat-
tern of weight change, including hsCRP,
HDL-C, RBP4, and the adipokines vaspin
and adiponectin, whose dynamic patterns
closely corresponded to each other,
suggesting a cumulative improvement in
the same direction (pattern B). However,
our statistical approach does not allow
deﬁning whether the distance of a speciﬁc
biomarkerpatternfromtheweightchange
pattern is statistically signiﬁcant.
TheDIRECTincludedlow-fat,Med-
iterranean, and low-carbohydrate die-
tary intervention arms in which unique
dietary compositions with respect to
carbohydrate, total fat, cholesterol, and
monounsaturated-to-saturated fat intake
were documented. We next assessed
whether the dynamics in the aforemen-
tioned parameters depended on the di-
etary strategy (Fig. 2). Although there
were (for some biomarkers) signiﬁcant
differences in the extent of the effects of
thedietarystrategiesonthechangesofspe-
ciﬁc biomarkers (3), the three diets simi-
larly exhibited the distinct two patterns of
dynamics. Both patterns were also similar
across sex and type 2 diabetic groups (data
not shown).
CONCLUSIONSdIn this study, we
analyzed the circulating levels of tradi-
tional biomarkers and commonand more
recently discovered adipokines and their
dynamics during 2 years of dietary inter-
vention, using both a nonbiased mathe-
matical modeling approach and qualitative
analysis. We found that the adipokines
leptin, chemerin, and MCP-1 correspond
tobodyweightdynamics,similartoplasma
insulin and serum TG levels. In contrast,
HMW adiponectin, fetuin-A, progranulin,
and vaspin exhibited cumulative change
despite partial weight regain, similar to the
changes in hsCRP and HDL-C.
Pattern B dynamics may reﬂect
either a delayed effect of the initial weight
lossoracontinuousbeneﬁcialresponseto
switching to healthier dietary patterns.
The two distinct biomarker patterns sug-
gestdifferentunderlyingbiologicalmech-
anisms through which these biomarkers
cluster together during different phases
of weight loss and maintenance. Even
the classical adipokines leptin (pattern A)
and adiponectin (pattern B) seem to re-
ﬂect different biological processes asso-
ciatedwithweightlossandweightregain:
Changes in circulating leptin are a func-
tion of changes in fat mass, whereas adipo-
nectin serum concentrations may reﬂect
changesinadiposetissuefunctionbeyond
the effects on fat mass. We therefore
hypothesize that biomarkers cluster in
pattern A because they directly reﬂect
body (fat) mass dynamic. This hypothesis
is further supported by several intercorre-
lations among parameters of pattern A. In
contrast, parameters in pattern B may
reﬂect alterations in other or in addition
to fat mass–related biological mecha-
nisms, including improved chronic sub-
clinical inﬂammation (as reﬂected by
intercorrelations with CRP), adipose tissue
function (as reﬂected by intercorrelations
with adiponectin), or lipid metabolism (as
reﬂected by intercorrelations with HDL-C)
upon diet interventions.
Regardless of the yet-to-be-discovered
mechanisms linking healthful diet and
beneﬁcial health effects independent of
body weight dynamics, we demonstrate
that 1) sustained moderate weight loss is
sufﬁcient to improve insulin and TG lev-
els, and 2) adhering to long-term dietary
intervention, even when experiencing
body weight plateau or partial regain, re-
sults in clinically relevant cumulatively
improvedHDL-C,adiponectin,andhsCRP
levels.
Our study has several limitations,
including the fact that only a few female
participants were studied. The statisti-
cal approach does not allow deﬁning
whether the distance of a speciﬁcb i o -
marker pattern from the weight change
pattern is statistically signiﬁcant or not.
We relied on self-reported dietary intake,
but we validated the dietary assessment
in two different dietary-assessment tools
(FFQs and food diaries) and one sub-
jective questionnaire, asking the partici-
pants about the extent of their adherence
to the assigned diet, and used electronic
questionnaires to minimize missing data.
The unique nature of the workplace in
this study, which permitted a closely mon-
itored dietary intervention for 2 years,
makes it difﬁcult to generalize the results
to other free-living conditions. However,
we believe that similar strategies to main-
tainadherencecouldbeappliedelsewhere
and should be used. Finally, in these
analyses, the end points constituted
changes in biomarkers, which are only
surrogate markers for cardiometabolic
disease risk. Yet some of these biomarkers
(hsCRP, adiponectin, and HDL-C) are
well-documented biomarkers of disease
risk, whereas data of the clinical relevance
of other markers is still accumulating. The
strengths of the study include the one-
phase design in which all participants
started simultaneously, the long duration
of the study, the relatively large study-
groupsize,thehighrateofadherence,and
the comprehensive list of traditional bio-
markers and novel adipokines.
Our data suggest that reduction in
circulating TGs and insulin could be
achieved only if weight loss, even if mod-
erate, is maintained. TGs, as a sensitive
biomarker of lifestyle, were recently re-
viewedinanewscientiﬁcstatementofthe
American Heart Association (17), which
concluded that lifestyle interventions
(diet and exercise) are the key factors for
treating hypertriglyceridemia. Weight
loss is an established treatment option to
improve insulin sensitivity in patients
346 DIABETES CARE, VOLUME 35, FEBRUARY 2012 care.diabetesjournals.org
Adipokine dynamics and weight losswithtype2diabetes(18).Itisnoteworthy
that fasting plasma insulin concentra-
tion has been shown to be the best pre-
dictor of higher baseline carotid vessel
wall volume in the DIRECT study pop-
ulation (19).
Our ﬁnding that increases in circulat-
ing HDL-C and HMW adiponectin and
decreases in hsCRP levels continued in a
cumulative manner throughout the en-
tire study period may be clinically im-
portant. Although it is clear that
adiponectinandCRParestrongmarkers
for the development of chronic disease, the
best strategy to favorably alter the inﬂam-
matory response is uncertain (20). We
previously reported that increased HDL-C
and apoA1 are associated with a signiﬁcant
regression in carotid vessel wall volume
achievedwithin2yearsoftheDIRECT(19).
As suggested by the hierarchical clus-
tering analysis, leptin has the closest
dynamic to weight changes, followed by
insulin. Adipokines may play a role as
signals from adipose tissue to the brain,
directly contributing to weight regain, or
at least as predictors of body weight dy-
namics. Although metabolic, behavioral,
neuroendocrine, and autonomic respon-
ses all contribute to the maintenance of
body energy stores at a deﬁned state, part
of the opposition to sustained weight loss
can be attributed to leptin (21). Circulat-
ing leptin levels and leptin mRNA expres-
sion highly correlate with adipose tissue
mass and, thus, can be used as surrogate
parameters for changes in the amount of
adipose tissue (22). We recently reported
that plasma leptin reduction, combined
Figure 2dDynamics of biomarkers in the three different dietary interventions. The two distinct patterns (A and B) of biomarkers were conﬁrmed
with differences in the extent across low-fat, Mediterranean, and low-carbohydrate groups during 2 years of dietary weight loss intervention. At
baseline, for all 12 displayed biomarkers, no signiﬁcant differences were found between the diet groups. At 6 months, signiﬁcant differences (P ,
0.05) were found between all diet groups for TGs, between the Mediterranean diet and the other diets for MCP-1 and Fetuin-A, between the low-fat
diet and the other diets for adiponectin and RBP4, and between the low-carbohydrate diet and the other diets for HDL-C and vaspin. At 24 months,
signiﬁcantdifferenceswerefoundbetweenalldietgroupsforCRP,betweentheMediterraneandietandtheotherdietsforvaspin,betweenthelow-fat
diet and the other diets for TGs, and between the low-carbohydrate diet and the other diets for HDL-C. The following statistically signiﬁcant
differences(P,0.05forall)werefoundbetweentimepointswithinthedietgroups:1)Low-fatgroup,0–6months:CRP,leptin,TG,HDL-C,insulin,
adiponectin, MCP-1, vaspin, fetuin-A, and chemerin; 6–24 months: CRP, leptin, TG, HDL-C, insulin, adiponectin, MCP-1, vaspin, fetuin-A, and
chemerin;0–24months:CRP,leptin,HDL-C,insulin,adiponectin,progranulin,andfetuin-A;2)Mediterraneangroup,0–6months:CRP,leptinTG,
HDL-C, insulin, adiponectin, MCP-1, vaspin, fetuin-A, chemerin, RBP4, and progranulin; 6–24 months: CRP, leptin, TG, HDL-C, insulin, adi-
ponectin,MCP-1,vaspin,fetuin-A,chemerin,andprogranulin;0–24months:CRP,leptin,TG,HDL-C,insulin,adiponectin,vaspin,fetuin-A,RBP4,
andprogranulin;and3)Low-carbohydrategroup,0–6months:CRP,leptin,TG,HDL-C,insulin,adiponectin,MCP-1,vaspin,chemerin,RBP4,and
progranulin;6–24months:CRP,leptin,TG,HDL-C,insulin,adiponectin,MCP-1,vaspin,fetuin-A,chemerin,andprogranulin;0–24months:CRP,
leptin, TG, HDL-C, insulin, adiponectin, vaspin, fetuin-A, RBP4, and progranulin.
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Blüher and Associateswith the degree of initial weight loss and
with genetic variations in the leptin gene,
constitutes a signiﬁcant predictor of sub-
sequent long-term weight regain (6). Ad-
ditional adipokines signal the functional
status of adipose tissue to other tissues
and frequently reﬂect weight changes.
In our study, chemerin, MCP-1, and
RBP4 serum concentrations correspon-
ded to body weight dynamics. Our data
of chemerin dynamic are in contrast to
a recent study demonstrating that a de-
crease in circulating chemerin concentra-
tions occurs despite weight maintenance
after bariatric surgery (23). Chemerin, a
proinﬂammatory protein, is highly ex-
pressed in the liver and adipose tissue
a n di sa s s o c i a t e dw i t hi m p a i r e di n s u l i n
sensitivity, altered glucose, and lipid me-
tabolism,withadualroleininﬂammation
andmetabolism(7).MCP-1,primarilyse-
creted by monocytes and macrophages,
is a potent proinﬂammatory chemokine.
It is synthesized by adipose tissue, ele-
vated in obesity, and has a role in mono-
cyte recruitment and, apparently, in the
developmentoftype2diabetes(8).RBP4,
secreted by adipocytes and hepatocytes,
correlates with the degree of obesity, in-
sulinresistance,visceralfataccumulation,
andfastingglucose(11–13).Inourstudy,
chemerin, MCP-1, and RBP4 serum con-
centration patterns closely followed the
body weight pattern, suggesting that
these adipokines reﬂect rather than cause
changes in body weight.
In contrast, the adipokines fetuin-A,
progranulin, and vaspin exhibited cumu-
lative improvement despite partial weight
regain throughout the study. Fetuin-A, a
glycoprotein synthesized by hepatocytes,
is associated with insulin resistance and
fataccumulationintheliverinhumans(10).
Progranulin levels are associated with
macrophage inﬁltration into omental adi-
posetissueandwithmarkersofinﬂamma-
tion, hyperglycemia, and predominantly
visceral fat accumulation (9). Vaspin, sug-
gested as a visceral adipose tissue–derived
factor, is associated with obesity and im-
pairedinsulinsensitivity(14).Ourdataon
the dynamics of fetuin-A, progranulin,
and vaspin during the long-term diet in-
tervention suggest that these adipokines
are directly linked to reduced food intake
and/or diet intervention effects, which are
independent of body weight dynamics.
Becauseinsulinsensitivityandcarotidves-
sel wall volume (19) are improved during
the entire DIRECT, fetuin-A, progranulin,
and vaspin serum concentrations may
provide a mechanistic link between
healthful diet and improvements in these
obesity-related parameters.
The two patterns of dynamics de-
scribed herein were similarly observed
among the three intervention arms that
wereproven to bedistinct indietary com-
position. Although our study may be un-
derpowered to detect minor differences
betweenthethreearms,itisalsoplausible
that factors common to the three diets are
major drivers of the change in the various
parameters. One obvious common factor
is the degree of caloric and total food
weight deﬁcit achieved (5), which was
similar between the three dietary groups
despite the fact that the low-carbohydrate
groupwasnotinstructedtorestrictcaloric
intake. Yet additional dietary changes
werecommontothethreearms,including
decreaseintransfattyacidsandsweetened
beverages and increase in vegetables and
ﬁber. Although we were unable to link a
speciﬁc dietary component to a particular
parameter, this is an important area for
future research, because speciﬁcd i e t a r y
factors could then be implemented in
larger public health measures to combat
obesity-associated morbidity, regardless
of whether they are part of a more com-
prehensive dietary change.
Inconclusion,wedemonstrateforthe
ﬁrst time that two major classes of dy-
namics of biomarkers can be described
during long-term diet interventions. One
pattern closely reﬂects weight change,
and the other is suggestive of cumulative
beneﬁcialeffects,alternativelyasadelayed
response to the initial weight loss or per-
haps to continued healthful dieting. Thus,
weight reduction is not the sole indicator
ofthebeneﬁcialeffectsofhealthfuldieting,
which may be discernable by measuring a
speciﬁc group of biomarkers despite par-
tial weight maintenance/regain.
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